Hua Medicine (Shanghai) Ltd.

SEHK:2552 주식 보고서

시가총액: HK$1.5b

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Hua Medicine (Shanghai) 관리

관리 기준 확인 3/4

Hua Medicine (Shanghai)'s CEO는 Li Chen, Jun2010 에 임명되었습니다 의 임기는 14.08 년입니다. 총 연간 보상은 CN¥ 17.08M, 33.6% 로 구성됩니다. 33.6% 급여 및 66.4% 보너스(회사 주식 및 옵션 포함). 는 HK$ 59.81M 가치에 해당하는 회사 주식의 3.96% 직접 소유합니다. 59.81M. 경영진과 이사회의 평균 재임 기간은 각각 4.4 년과 5.8 년입니다.

주요 정보

Li Chen

최고 경영자

CN¥17.1m

총 보상

CEO 급여 비율33.6%
CEO 임기14.1yrs
CEO 소유권4.0%
경영진 평균 재임 기간4.4yrs
이사회 평균 재임 기간5.8yrs

최근 관리 업데이트

Recent updates

Is Hua Medicine (Shanghai) (HKG:2552) Using Too Much Debt?

Nov 17
Is Hua Medicine (Shanghai) (HKG:2552) Using Too Much Debt?

Investors Appear Satisfied With Hua Medicine (Shanghai) Ltd.'s (HKG:2552) Prospects

Aug 28
Investors Appear Satisfied With Hua Medicine (Shanghai) Ltd.'s (HKG:2552) Prospects

We Think Hua Medicine (Shanghai) (HKG:2552) Can Afford To Drive Business Growth

Jan 06
We Think Hua Medicine (Shanghai) (HKG:2552) Can Afford To Drive Business Growth

We're Interested To See How Hua Medicine (Shanghai) (HKG:2552) Uses Its Cash Hoard To Grow

Aug 02
We're Interested To See How Hua Medicine (Shanghai) (HKG:2552) Uses Its Cash Hoard To Grow

Companies Like Hua Medicine (Shanghai) (HKG:2552) Can Afford To Invest In Growth

Apr 22
Companies Like Hua Medicine (Shanghai) (HKG:2552) Can Afford To Invest In Growth

Companies Like Hua Medicine (Shanghai) (HKG:2552) Can Afford To Invest In Growth

Sep 23
Companies Like Hua Medicine (Shanghai) (HKG:2552) Can Afford To Invest In Growth

We're Not Worried About Hua Medicine (Shanghai)'s (HKG:2552) Cash Burn

Jun 24
We're Not Worried About Hua Medicine (Shanghai)'s (HKG:2552) Cash Burn

Companies Like Hua Medicine (Shanghai) (HKG:2552) Can Afford To Invest In Growth

Mar 22
Companies Like Hua Medicine (Shanghai) (HKG:2552) Can Afford To Invest In Growth

Hua Medicine (Shanghai) Ltd.'s (HKG:2552) Profit Outlook

Feb 21
Hua Medicine (Shanghai) Ltd.'s (HKG:2552) Profit Outlook

Hua Medicine (Shanghai) (HKG:2552) Shareholders Booked A 21% Gain In The Last Year

Jan 25
Hua Medicine (Shanghai) (HKG:2552) Shareholders Booked A 21% Gain In The Last Year

Hua Medicine (Shanghai) (HKG:2552) Is In A Strong Position To Grow Its Business

Dec 21
Hua Medicine (Shanghai) (HKG:2552) Is In A Strong Position To Grow Its Business

CEO 보상 분석

Li Chen 의 보수는 Hua Medicine (Shanghai) 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Dec 31 2023CN¥17mCN¥6m

-CN¥211m

Sep 30 2023n/an/a

-CN¥200m

Jun 30 2023n/an/a

-CN¥189m

Mar 31 2023n/an/a

-CN¥196m

Dec 31 2022CN¥23mCN¥5m

-CN¥204m

Sep 30 2022n/an/a

-CN¥234m

Jun 30 2022n/an/a

-CN¥265m

Mar 31 2022n/an/a

-CN¥295m

Dec 31 2021CN¥24mCN¥5m

-CN¥326m

Sep 30 2021n/an/a

-CN¥355m

Jun 30 2021n/an/a

-CN¥385m

Mar 31 2021n/an/a

-CN¥389m

Dec 31 2020CN¥28mCN¥5m

-CN¥393m

Sep 30 2020n/an/a

-CN¥378m

Jun 30 2020n/an/a

-CN¥363m

Mar 31 2020n/an/a

-CN¥394m

Dec 31 2019CN¥28mCN¥4m

-CN¥425m

Sep 30 2019n/an/a

-CN¥1b

Jun 30 2019n/an/a

-CN¥2b

Mar 31 2019n/an/a

-CN¥3b

Dec 31 2018CN¥12mCN¥2m

-CN¥4b

Sep 30 2018n/an/a

-CN¥3b

Jun 30 2018n/an/a

-CN¥2b

Mar 31 2018n/an/a

-CN¥440m

Dec 31 2017CN¥4mCN¥3m

-CN¥273m

보상 대 시장: Li 의 총 보상 ($USD 2.35M )은 Hong Kong 시장( $USD 351.75K ).

보상과 수익: Li 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.


CEO

Li Chen (61 yo)

14.1yrs

테뉴어

CN¥17,083,000

보상

Dr. Li Chen, Ph.D. is the Co-Founder of Hua Medicine (Shanghai) Ltd. and served as its Chief Scientific Officer until 2022 and served as its President until May 19, 2016 and has been its Chief Executive Of...


리더십 팀

이름위치테뉴어보상소유권
Li Chen
Founder14.1yrsCN¥17.08m3.96%
CN¥ 58.6m
Chien Cheng Lin
Executive VP1.3yrsCN¥7.16m0.87%
CN¥ 12.8m
Fuxing Tang
CTO, VP of Chemical Manufacturing Control Department and Head of R&D in USA4.4yrs데이터 없음데이터 없음
Changhong Li
Chief Scientific Officer1.6yrs데이터 없음데이터 없음
Chengde Wang
Head of IRno data데이터 없음데이터 없음
Yi Zhang
Senior VP of Pharma Development6.3yrs데이터 없음데이터 없음
Ying Xie
VP of Quality Assurance Division & Chief Quality Officer1.2yrs데이터 없음데이터 없음
Wing Yan Yuen
Company Secretary4.6yrs데이터 없음데이터 없음

4.4yrs

평균 재임 기간

55yo

평균 연령

경험이 풍부한 관리: 2552 의 관리팀은 경험 ( 4.3 년 평균 재직 기간)으로 간주됩니다.


이사회 구성원

이름위치테뉴어보상소유권
Li Chen
Founder14.1yrsCN¥17.08m3.96%
CN¥ 58.6m
Chien Cheng Lin
Executive VP6.2yrsCN¥7.16m0.87%
CN¥ 12.8m
Yi Zhang
Senior VP of Pharma Developmentless than a year데이터 없음데이터 없음
Robert Taylor Nelsen
Non-Executive Chairman14.3yrs데이터 없음0.015%
CN¥ 226.5k
Bennett Shapiro
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Yiu Wa Tsui
Independent Non-Executive Director5.8yrsCN¥450.00k0.0024%
CN¥ 36.3k
Catherine D. Strader
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
William Robert Keller
Independent Non-Executive Director5.8yrsCN¥540.00k데이터 없음
James MacDonald
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Yiu Leung Cheung
Independent Non-Executive Director1.5yrsCN¥540.00k데이터 없음
Fangxin Li
Non-Executive Directorless than a year데이터 없음데이터 없음

5.8yrs

평균 재임 기간

63yo

평균 연령

경험이 풍부한 이사회: 2552 의 이사회경험(평균 재직 기간 5.8 년)으로 간주됩니다.